Brief: Tourmaline Bio Presents Phase 2 Tranquility Study Design At American Society Of Preventive Cardiology Congress 2024
02/08/2024 23:13
Aug 2 (Reuters) - Tourmaline Bio Inc TRML.O :
* TOURMALINE BIO PRESENTS PHASE 2 TRANQUILITY STUDY DESIGN
AT
AMERICAN SOCIETY OF PREVENTIVE CARDIOLOGY (ASPC) CONGRESS 2024
* TOPLINE DATA IS EXPECTED FIRST HALF OF 2025
Source text for Eikon: ID:nGNX1s5gk6
Further company coverage: TRML.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy